Centre Bans 16 Fixed-Dose Combination Drugs Over Safety Concerns

The Union Ministry of Health has banned 16 Fixed-Dose Combination (FDC) drugs citing safety concerns, lack of proven efficacy, and deviation from rational drug use principles. This regulatory action reflects ongoing efforts to rationalize pharmaceutical offerings and protect public health.

BACKGROUND: FDCs combine two or more active pharmaceutical ingredients in fixed proportions. While convenient, many FDCs lack robust clinical evidence supporting their efficacy, lack patient dose flexibility, and may lead to unnecessary drug exposure. India's drug regulator (DCGI under Ministry of Health) periodically reviews and bans problematic formulations.

KEY FACTS: The 16 banned drugs had various compositions; bans were issued after review by pharmaceutical advisory bodies. Such actions follow periodic audits of FDCs against international standards and clinical evidence. Previous ban waves occurred in 2019 and 2023, affecting hundreds of FDCs. Currently, India has thousands of approved FDCs but faces regulatory challenges in enforcement.

WHY IT MATTERS: Protects consumers from potentially harmful medications; reduces irrational polypharmacy; aligns with WHO guidelines on essential medicines; improves healthcare quality; addresses medication safety—constitutional right to health (Article 21).

EXAM ANGLE: Pharmaceutical regulation; DCGI authority; Drug and Cosmetics Act provisions; Essential Medicines concept; Public Health administration; Medicine prices regulation (NLEM); Consumer protection; UPSC Mains (Public Health/Administration); State PSC; likely factual questions in Prelims.